Prion urine comprises a glycosaminoglycan-light chain IgG complex that can be stained by Congo red

被引:8
作者
Halimi, M [1 ]
Dayan-Amouyal, Y [1 ]
Kariv-Inbal, Z [1 ]
Friedman-Levi, Y [1 ]
Mayer-Sonnenfeld, T [1 ]
Gabizon, R [1 ]
机构
[1] Hadassah Univ Hosp, Dept Neurol, Agnes Ginges Ctr Human Neurogenet, IL-91120 Jerusalem, Israel
关键词
urine; CJD; Congo red; light chain IgG; prion; glycosaminoglycans;
D O I
10.1016/j.jviromet.2005.11.011
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Light chain IgG, a known amyloidotic protein, is present in the urine of prion disease affected individuals in a protease resistant form. In addition, it was shown recently that prion urine samples comprise a significant excess of glycosaminoglycans. Since amyloidotic proteins and glycosaminoglycans are the major components of amyloid aggregates, a Congo red dot blot assay was developed for detection of Creutzfeldt-Jacob disease (CJD) in urine. This assay was also positive for about 10% of patients suffering from diseases such as Alzheimer disease, cerebrovascular attacks and multiple sclerosis, but negative for healthy controls. Both glycosaminoglycans and proteins such as light chain IgG were required for the binding of Congo red to the urine fractions, as shown by the fact that Proteinase K digestion of the samples either after guanidine or after choindrotinase abolished the Congo red signal from the CJD samples. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:205 / 210
页数:6
相关论文
共 29 条
[1]   vCJD tissue distribution and transmission by transfusion - a worst-case scenario coming true? [J].
Aguzzi, A ;
Glatzel, M .
LANCET, 2004, 363 (9407) :411-412
[2]   SULFATED POLYANION INHIBITION OF SCRAPIE-ASSOCIATED PRP ACCUMULATION IN CULTURED-CELLS [J].
CAUGHEY, B ;
RAYMOND, GJ .
JOURNAL OF VIROLOGY, 1993, 67 (02) :643-650
[3]   Biology and therapy of immunoglobulin deposition diseases [J].
Dhodapkar, MV ;
Merlini, G ;
Solomon, A .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (01) :89-&
[4]   Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases [J].
Díaz-Nido, J ;
Wandosell, F ;
Avila, J .
PEPTIDES, 2002, 23 (07) :1323-1332
[5]   Emerging infectious threats to the blood supply [J].
Dodd, RY ;
Leiby, DA .
ANNUAL REVIEW OF MEDICINE, 2004, 55 :191-207
[6]   Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy [J].
Elimova, E ;
Kisilevsky, R ;
Szarek, WA ;
Ancsin, JB .
FASEB JOURNAL, 2004, 18 (12) :1749-+
[7]  
Hazenberg BPC, 2004, NETH J MED, V62, P121
[8]   Evaluation of urinary PrPSc as a diagnostic test for sporadic, variant, and familial CJD [J].
Head, MW ;
Kouverianou, E ;
Taylor, L ;
Green, A ;
Knight, R .
NEUROLOGY, 2005, 64 (10) :1794-1796
[9]   PrPSc incorporation to cells requires endogenous glycosaminoglycan expression [J].
Hijazi, N ;
Kariv-Inbal, Z ;
Gasset, M ;
Gabizon, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (17) :17057-17061
[10]   Heparan sulfate is a cellular receptor for purified infectious prions [J].
Horonchik, L ;
Tzaban, S ;
Ben-Zaken, O ;
Yedidia, Y ;
Rouvinski, A ;
Papy-Garcia, D ;
Barritault, D ;
Vlodavsky, I ;
Taraboulos, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (17) :17062-17067